President Donald Trump directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine. The administration is taking steps to ease access to psychedelics that Trump said were already designated as potential breakthroughs by federal regulators. The Food and Drug Administration next week will issue national priority vouchers for three psychedelics. FDA Commissioner Marty Makary said the vouchers will allow certain drugs to be approved quickly if they are in line with national priorities. It is the first time the FDA has offered that fast-tracking to any psychedelics.
Ibogaine is banned under the federal government's most restrictive category for illegal, high-risk drugs. Veteran organizations and psychedelic advocates have long contended that ibogaine has great promise for hard-to-treat conditions such as post-traumatic stress disorder and opioid addiction. However, ibogaine is known to sometimes trigger potentially fatal heart problems, which has contributed to its controversial status.
The National Institutes of Health briefly funded research on ibogaine in the 1990s, but discontinued the work due to ibogaine's cardiovascular toxicity. It has been incredibly difficult to study ibogaine in the U.S. because of its known cardiotoxicity, presenting historical and ongoing challenges for researchers.
The FDA is also taking steps to clear the way for the first-ever human trials of ibogaine in the United States. The timeline for these trials has not been announced. Beyond the executive order, the specific steps the administration is taking to ease access to psychedelics have not been fully outlined. Additionally, which specific psychedelic drugs besides ibogaine are included in the executive order remains unknown.